'Enteral' hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man
- PMID: 883468
'Enteral' hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man
Abstract
The effect of oral administration of cholestyramine, neomycine, calcium, and bile acids on intestinal 14C-oxalate absorption and urinary oxalate excretion was assessed in patients with normal or increased ('enteric' hyperoxaluria) urinary oxalate excretion. Cholestyramine, neomycine and acute administration of chenodeoxycholic acid (2.75 g/24 h) did not affect significantly 14C-oxalate absorption or urinary oxalate excretion. Oral administration of calcium markedly reduced 14C-oxalate absorption (88.2%) and urinary oxalate excretion (46%). Calcium-induced reduction of intestinal oxalate absorption was more pronounced in patients with hyperabsorption of oxalate than in subjects with normal oxalate absorption or excretion. Patients on treatment with high doses of chenodeoxycholic acid (1.5-2.0 g/day) for dissolution of cholesterol gallstones had increased oxalate absorption and excretion, patients on long-term treatment with lower doses of chenodeoxycholic acid (0.75-1.0 g/day) exhibited normal absorption or urinary excretion of oxalate. The results do suggest that calcium and bile acids do play an important role in the pathogenesis of 'enteric' hyperoxaluria. It is suggested that the beneficial therapeutic effect of cholestyramine in hyperoxaluria due to ileal resection is rather caused by its bile acid binding property than by direct binding of oxalate within the intestinal lumen.
Similar articles
-
Effects of calcium, aluminium, magnesium and cholestyramine on hyperoxaluria in patients with jejunoileal bypass.Acta Chir Scand. 1983;149(1):93-8. Acta Chir Scand. 1983. PMID: 6837229
-
Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption.Scand J Urol Nephrol Suppl. 1989;119:1-53. Scand J Urol Nephrol Suppl. 1989. PMID: 2669121 Review.
-
Intestinal oxalate absorption. I. Absorption in vitro.Res Exp Med (Berl). 1977 Aug 16;171(1):13-24. doi: 10.1007/BF01851584. Res Exp Med (Berl). 1977. PMID: 410086
-
Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate.J Am Soc Nephrol. 1999 Nov;10 Suppl 14:S329-33. J Am Soc Nephrol. 1999. PMID: 10541257
-
[Hyperoxaluria and renal calculi].Arch Esp Urol. 1996 Sep;49(7):707-26. Arch Esp Urol. 1996. PMID: 9020008 Review. Spanish.
Cited by
-
The management of patients with enteric hyperoxaluria.Urolithiasis. 2016 Feb;44(1):33-43. doi: 10.1007/s00240-015-0846-5. Epub 2015 Dec 8. Urolithiasis. 2016. PMID: 26645872 Review.
-
[Enteric hyperoxaluria. I. Intestinal oxalate absorption in gastrointestinal diseases (author's transl)].Klin Wochenschr. 1978 Jun 15;56(12):607-15. doi: 10.1007/BF01477009. Klin Wochenschr. 1978. PMID: 682526 German.
-
Guidelines for management of patients with a short bowel.Gut. 2006 Aug;55 Suppl 4(Suppl 4):iv1-12. doi: 10.1136/gut.2006.091108. Gut. 2006. PMID: 16837533 Free PMC article. No abstract available.
-
Risk Factors for Kidney Stone Formation following Bariatric Surgery.Kidney360. 2020 Dec;1(12):1456-1461. doi: 10.34067/kid.0004982020. Epub 2020 Dec 31. Kidney360. 2020. PMID: 34085046 Free PMC article.
-
Dietary Management of Chronic Kidney Disease and Secondary Hyperoxaluria in Patients with Short Bowel Syndrome and Type 3 Intestinal Failure.Nutrients. 2022 Apr 14;14(8):1646. doi: 10.3390/nu14081646. Nutrients. 2022. PMID: 35458207 Free PMC article. Review.